In late January, Samsung Bioepis announced that its biosimilar of Amgen’s Enbrel (etanercept), used to treat autoimmune diseases, was accepted for review by EMA. Amgen’s patents on Enbrel set to expire in August 2015.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
